Merck KGaA taps CRUK, ICR for source of cancer candidates

Merck kgaa
The multiproject collaboration builds on earlier, single-program discovery pacts between the groups. (Image: Merck KGaA)

Merck KGaA has teamed up with Cancer Research UK (CRUK) to access cancer candidates. The pact sets Merck up to work with researchers at CRUK’s unit at The Institute of Cancer Research (ICR) on three preclinical oncology projects.

Details of the projects are scarce. The scope of the collaboration spans from target hit discovery to preclinical candidate nomination. Beyond that, little is known publicly about the projects.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

The collaborators have been somewhat more forthcoming about the structure of the deal. Merck will work with CRUK and ICR to move the projects through discovery and preclinical development, while also advancing biomarkers for target engagement and patient selection. Once the candidates get to the clinic, Merck will take the programs forward and hold worldwide rights.

CRUK and ICR will receive milestone payments, and potentially royalties, In return for their early contributions to the programs. 

The multiproject collaboration builds on earlier, single-program discovery pacts between the groups, plus a target validation alliance, and further strengthens ties between Merck and CRUK’s units. Merck and CRUK have entered into multiple agreements over the past decade, from a 2009 pact focused on the WNT signalling pathway up to last year’s creation of immuno-oncology startup iOnctura.

RELATED: Merck Ventures, CRUK launch new immuno-oncology spinout biotech iOnctura

The agreements give Merck access to innovation from beyond its walls by connecting it to the work of cancer researchers at sites across the U.K. The ultimate success of those projects will go some way to dictating whether the coming decade is more fruitful for Merck’s R&D team than the last, during which it struggled to get new drugs to market.

CRUK thinks the latest collaboration could give Merck access to drugs that treat multiple tumors.  

“We hope that through the diverse projects in this collaboration, we can identify molecules that are effective against a number of different tumor types,” Raj Chopra, M.D., Ph.D., director of CRUK’s cancer therapeutics unit at the ICR, said in a statement.

Suggested Articles

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.